<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04410367</url>
  </required_header>
  <id_info>
    <org_study_id>BED-FLC-219</org_study_id>
    <nct_id>NCT04410367</nct_id>
  </id_info>
  <brief_title>Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)</brief_title>
  <acronym>PURSUE</acronym>
  <official_title>An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Earth Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Precision For Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blue Earth Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish&#xD;
      Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in&#xD;
      Detecting Recurrent Brain Metastases After Radiation Therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Positron Emission Tomography (PET) Imaging study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of different thresholds of lesion 18F fluciclovine uptake on visual reads .</measure>
    <time_frame>60 days</time_frame>
    <description>Sensitivity of different thresholds of lesion 18F fluciclovine uptake on visual reads compared to central histopathological analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of different thresholds of lesion 18F fluciclovine uptake on visual reads.</measure>
    <time_frame>60 days</time_frame>
    <description>Specificity of different thresholds of lesion 18F fluciclovine uptake on visual reads compared to central histopathological analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake.</measure>
    <time_frame>60 days</time_frame>
    <description>Sensitivity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake compared to central histopathological analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake.</measure>
    <time_frame>60 days</time_frame>
    <description>Specificity of different thresholds of quantitative and dynamic measures of lesion 18F fluciclovine uptake compared to central histopathological analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>2 days post-18F-fluciclovine administration</time_frame>
    <description>Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 2 days post-18F-fluciclovine administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of 18F fluciclovine for PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F fluciclovine</intervention_name>
    <description>18F fluciclovine injection, 185 MBq (5 mCi) Â± 20%, delivered as an intravenous bolus</description>
    <arm_group_label>Patients</arm_group_label>
    <other_name>Axumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          2. Previous history of solid tumor brain metastasis of any origin&#xD;
&#xD;
          3. Histopathological confirmation of the primary solid tumor or a metastatic site&#xD;
&#xD;
          4. Previous radiation therapy of brain metastatic lesion(s)&#xD;
&#xD;
          5. A reference lesion considered by the site investigator to be equivocal for recurrent&#xD;
             brain metastasis&#xD;
&#xD;
          6. Patient requires further confirmatory diagnostic procedures to confirm brain MRI&#xD;
             findings and is planned for craniotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients with a history of active hematological malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keren Ronk</last_name>
    <phone>+1 832.841.9794</phone>
    <email>keren.ronk@precisionformedicine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Providence St. John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffi Nersesian</last_name>
      <phone>310-829-8808</phone>
      <email>nersesianR@jwci.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen DeFrancesco</last_name>
      <phone>203-785-5182</phone>
      <email>kristen.defrancesco@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Avendano</last_name>
      <phone>786-527-8695</phone>
      <email>MariaAve@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neydin Tejeda</last_name>
      <phone>504-703-5577</phone>
      <email>neydin.tejeda@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Center for Clinical Imaging Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Frye</last_name>
      <phone>314-747-1604</phone>
      <email>fryej@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Keller</last_name>
      <phone>929-455-2453</phone>
      <email>Rachael.Keller@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Kardan</last_name>
      <email>arash.kardan@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Kry</last_name>
      <phone>267-760-0148</phone>
      <email>yolanda.kry@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Quantitative Cancer Imaging at Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hoffman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Brain Metastases</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Positron Emission Tomography (PET) Scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

